Leonardo Portocarrero-Sánchez

Dr. Leonardo Portocarrero-Sánchez


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2025 in Toxins
Verified
Journal Article
Open access
PDF file
ASAlejandro Sánchez-Huertas
Alejandro Sánchez-Huertas
OMOscar Camejo Mas
Oscar Camejo Mas
SGSebastian Garcia-Roldan
Sebastian Garcia-Roldan
RARocio Alonso-Castillo
Rocio Alonso-Castillo
LPLara Pulido-Fraiz
Lara Pulido-Fraiz
JDJavier Díaz-de-Terán
Javier Díaz-de-Terán
Interictal burden (IB), defined as the symptoms and impairments that occur between migraine attacks, including cognitive dysfunction, photophobia, and fatigue, is recognized as a significant determinant of quality of life in patients. A prospective observational study was conducted. Patients diagnosed with chronic migraine (CM) and under treatment with OnabotulinumtoxinA (OnabotA) according to the PREEMPT protocol (every 12 weeks) were assessed at baseline and at 3, 6, 9, and 12 months. The primary endpoint was to evaluate the change in the IB measured with the Migraine Interictal Burden Scale (MIBS-4) and in the monthly migraine days (MMD). The secondary endpoint was acute medication use. This single-center study included 150 patients (91.3% female; median age 44 years). MIBS-4 scores were decreased by 29.1% at 3 months (8.47 to 5.97) and by 41.6% at 12 months (to 4.86; p < 0.001). IB-free status was achieved by 16 patients (10.7%). The most disabling baseline symptoms were photophobia (37%), fatigue (20%), and allodynia (18%), which reduced by 52%, 43%, and 39% at 12 months, respectively. MMD were reduced from 18.6 to 8.3 days at 12 months and triptan and analgesic intake decreased by 58.7% and 55.4%. OnabotA significantly reduced both IB and migraine frequency over 12 months, underscoring its relevance in CM management.

14 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GMGerardo Ricardo Zmork Martinez
Gerardo Ricardo Zmork Martinez
AHAndrea Higuera-Ruiz-de-la-Hermosa
Andrea Higuera-Ruiz-de-la-Hermosa
LPLeonardo Portocarrero-Sánchez
Leonardo Portocarrero-Sánchez
JDJavier Díaz-de-Terán
Javier Díaz-de-Terán
Background/Objectives: Personality traits in patients with cluster headache (CH) remain understudied compared to migraine patients. This could help improve diagnosis, identify comorbidities, and provide more personalized management of CH. This study aimed to characterize the personality profiles of patients with CH and compare them with those of patients with migraine. Methods: This cross-sectional, case–control observational study was conducted at a tertiary hospital’s headache unit (May–August 2024). Patients with CH were compared with migraine patients and healthy controls. Demographic and clinical data were collected, and the Minnesota Multiphasic Personality Inventory-3 (MMPI-3) was administered. Results: The study included 28 CH patients (17 with episodic and 11 with chronic CH), 55 migraine patients (34 with episodic migraine and 21 with chronic migraine), and 54 healthy controls. Both patient groups reported significantly more somatic and cognitive complaints than controls (p < 0.05). Compared to controls, the migraine group exhibited greater emotional dysfunction, social avoidance, demoralization, introversion, and social anxiety (p < 0.05), while the CH group showed greater impulsivity (p < 0.05). Directly comparing patient groups, migraine patients displayed greater social avoidance, emotional dysfunction, demoralization, and introversion than the CH group (p < 0.05). CH patients also showed a non-significant trend towards behavioral disinhibition, hypomania, a favorable self-image, juvenile conduct problems, substance abuse, and aggressiveness. Patients with CH did not present a higher risk of suicide compared to migraine patients. Conclusions: This study identified distinct personality profiles: Migraine patients exhibited greater emotional and interpersonal dysfunction (internal distress and withdrawal), while CH patients exhibited greater externalizing behavioral dysfunction, predominantly involving impulsivity.

23 May 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
LPLeonardo Portocarrero-Sánchez
Leonardo Portocarrero-Sánchez
CRCristian Rizea
Cristian Rizea
MLMaría Alonso de Leciñana
María Alonso de Leciñana
MLMoisés León-Ruiz
Moisés León-Ruiz
JDJavier Díaz-de-Terán
Javier Díaz-de-Terán
Background/Objectives: Cluster headache (CH) is a debilitating primary headache disorder characterized by severe unilateral pain attacks. Chronic CH (CCH) poses significant treatment challenges, especially in refractory cases. Neuromodulation, including repetitive transcranial magnetic stimulation (rTMS), offers a potential alternative; however, evidence for its efficacy in CCH is lacking. Methods: A randomized, double-blind, placebo-controlled, crossover pilot study was conducted. Eligibility criteria included patients with refractory CCH (rCCH), who were then randomized to receive two treatment sequences: A, rTMS followed by sham stimulation, or B, sham followed by rTMS, separated by a one-month washout, with a follow-up period of 3 months. The primary endpoint was to analyze efficacy by assessing the change in the number of attacks per week (APW). Secondary endpoints included treatment tolerability and changes in intensity, duration, and use of rescue medication. The trial was registered with ClinicalTrials.gov (NCT06917144). Results: Eight patients were enrolled and randomized with a 50% probability of assignment to either treatment arm. Despite this, five patients were allocated to sequence A and three to sequence B. Three patients completed the entire study; five received treatment with rTMS and six with sham. The APW change during rTMS showed a change of (mean ± SD) +2.2 (10.8) attacks per week (p = 0.672). Two patients achieved complete remission during the rTMS phase, though symptoms returned by the washout period. In comparison with sham, the difference was also not statistically significant. No significant changes were observed in secondary endpoints. Side effects (two cases) were mild and transient. Conclusions: This pilot study suggests that rTMS may provide clinical benefits for rCCH in selected cases, though its effects seem transient. Adherence to treatment remains a critical challenge.

25 February 2026 in Brain Sciences
Verified
Journal Article
Open access
PDF file
LPLeonardo Portocarrero-Sánchez
Leonardo Portocarrero-Sánchez
AGAlfonso Gil-Martínez
Alfonso Gil-Martínez
JSJose F. Paz Solis
Jose F. Paz Solis
MRMaría Román-Aragón
María Román-Aragón
BMBeatriz Mansilla-Fernández
Beatriz Mansilla-Fernández
JDJavier Díaz-de-Terán
Javier Díaz-de-Terán
Background: Occipital nerve stimulation (ONS) is an effective therapy for patients with refractory chronic cluster headache (rCCH); however, it is not without complications, and to date, there are no conclusive findings regarding factors that would allow the prediction of treatment response. The primary objective of this study is to identify such factors to improve patient selection. Methods: This single-center prospective observational study will be conducted at the Department of Neurology, Hospital Universitario La Paz (Madrid, Spain). Given the low prevalence of rCCH, a convenience sampling approach will be adopted, with an expected enrollment of a minimum of 15 patients over 24 months of the study. The study is structured into three periods: Pre-ONS (pre-implantation), ONS (implantation), and Post-ONS (follow-up at 12 months). During the pre-implantation phase, patients will undergo a multidimensional assessment encompassing structural 3T brain magnetic resonance imaging (MRI), blood analysis (calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-activating peptide 38 (PACAP38), and vasoactive intestinal peptide (VIP)), neuropsychological evaluation, auditory evoked potentials, algometry (pressure pain threshold, temporal summation, conditioned pain modulation), and transcutaneous electrical nerve stimulation (TENS). Follow-up visits will be conducted at 3, 6, and 12 months post-implantation. Results: This study aims to identify biomarkers or their combinations capable of reliably predicting patients who would benefit from ONS. Conclusions: Through this multidimensional assessment, this study seeks to identify predictive factors of response to ONS, thereby improving patient selection, optimizing healthcare resources, and advancing the understanding of treatment response mechanisms.

10 October 2026 in Nursing Reports
Verified
Journal Article
Open access
PDF file
MCMaria Jose Ruiz Castrillo
Maria Jose Ruiz Castrillo
LPLeonardo Portocarrero-Sánchez
Leonardo Portocarrero-Sánchez
LZLucía Zaballa-Pérez
Lucía Zaballa-Pérez
ASAlejandro Sánchez-Huertas
Alejandro Sánchez-Huertas
JDJavier Díaz-de-Terán
Javier Díaz-de-Terán
Background/Objectives: Migraine is a leading cause of disability worldwide. Despite advances such as calcitonin gene-related peptide (CGRP)-targeted therapies, suboptimal treatment adherence, limited health literacy, and weak self-management remain common, and patient-reported data on the contribution of specialist headache nurses within European tertiary units are scarce. This study describes patient-reported adherence to acute treatment and to lifestyle recommendations, self-perceived knowledge, and perceived quality of life in adults with migraine who had attended a structured, nurse-led educational consultation in a tertiary multidisciplinary headache unit. Methods: This cross-sectional descriptive study included 90 adults (≥18 years) with migraine diagnosed according to the International Classification of Headache Disorders, third edition (ICHD-3), who were starting treatment with an anti-CGRP monoclonal antibody and consecutively attended a specialist nursing consultation; patients with documented cognitive impairment or without written informed consent were excluded. Between January and December 2021, participants completed, on a single occasion after the consultation, an electronic, structured, piloted ad hoc survey covering knowledge (with pre-consultation knowledge rated retrospectively), adherence to pharmacological and lifestyle recommendations, perceived changes in attack frequency and intensity, and self-reported quality of life. Data were analysed descriptively, with 95% confidence intervals (CIs) for proportions and without formal hypothesis testing. Results: Participants were mostly women (67.8%), with a mean age of 43.1 ± 10.7 years. Overall, 74.4% (95% CI 64.6–82.3) reported always following acute-treatment instructions and 66.7% (56.4–75.5) always following lifestyle recommendations; 68.9% (58.7–77.5) felt the education had improved their understanding of migraine and their quality of life, and 67.8% (57.6–76.5) perceived fewer attacks. Self-rated adequate knowledge was higher at the time of the survey than retrospectively recalled for the pre-consultation period in all five domains. The main barriers were limited prior knowledge and difficulty maintaining a headache diary. Conclusions: Most patients who had received structured nurse-led education reported good adherence and perceived benefits in their understanding of migraine and quality of life. Given the cross-sectional design, the retrospective assessment of prior knowledge, the use of a non-validated questionnaire, and the absence of a control group, these findings cannot be attributed to the consultation itself, and perceived changes in attack frequency cannot be separated from the effect of the newly started anti-CGRP treatment; prospective, controlled studies using validated outcome measures are needed. This study was not registered.